- Novo’s full-year sales reached DKK 290.40 billion, surpassing the estimated DKK 285.57 billion.
- Earnings before interest and taxes (EBIT) came in at DKK 128.34 billion, exceeding the forecasted DKK 125.96 billion.
- Net income for the year was DKK 100.99 billion, slightly above the anticipated DKK 100.26 billion.
- Earnings per share (EPS) were reported as DKK 22.63, slightly below the expected DKK 22.77.
- The stock received 23 buy recommendations, 8 hold recommendations, and 2 sell recommendations.
A look at Novo Nordisk A/S Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 3 | |
Growth | 5 | |
Resilience | 4 | |
Momentum | 2 | |
OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Novo Nordisk A/S, a leading pharmaceutical company, has received mixed feedback on its Smart Scores. While it excels in terms of growth and resilience, scoring a high 5 and 4 respectively, its value and momentum scores fall short at 2 each. This indicates that the company may be viewed as having strong potential for future expansion and the ability to withstand economic uncertainties. However, investors might be hesitant due to its current valuation and lack of short-term momentum.
Specializing in diabetes care and pharmaceutical products, Novo Nordisk A/S has a diverse product portfolio that includes insulin delivery systems and other diabetes-related offerings. Additionally, the company operates in fields like haemostatis management, growth disorders, and hormone replacement therapy, showcasing its commitment to healthcare innovation. Despite its varying Smart Scores, Novo Nordisk A/S remains a global player, providing educational resources and products to a wide market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars